504 related articles for article (PubMed ID: 19232036)
1. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.
Deniz HB; Ward A; Jaime Caro J; Alvarez P; Sadri H
Curr Med Res Opin; 2009 Mar; 25(3):617-26. PubMed ID: 19232036
[TBL] [Abstract][Full Text] [Related]
2. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone.
Caro JJ; Ward A; Deniz HB; O'Brien JA; Ehreth JL
Value Health; 2007; 10(1):13-22. PubMed ID: 17261112
[TBL] [Abstract][Full Text] [Related]
3. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
[TBL] [Abstract][Full Text] [Related]
4. SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
Au-Yeung WT; Reinhall PG; Poole JE; Anderson J; Johnson G; Fletcher RD; Moore HJ; Mark DB; Lee KL; Bardy GH
Heart Rhythm; 2015 Oct; 12(10):2058-66. PubMed ID: 26096609
[TBL] [Abstract][Full Text] [Related]
5. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
Klein H; Auricchio A; Reek S; Geller C
Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.
Owens DK; Sanders GD; Harris RA; McDonald KM; Heidenreich PA; Dembitzer AD; Hlatky MA
Ann Intern Med; 1997 Jan; 126(1):1-12. PubMed ID: 8992917
[TBL] [Abstract][Full Text] [Related]
7. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
Packer DL; Prutkin JM; Hellkamp AS; Mitchell LB; Bernstein RC; Wood F; Boehmer JP; Carlson MD; Frantz RP; McNulty SE; Rogers JG; Anderson J; Johnson GW; Walsh MN; Poole JE; Mark DB; Lee KL; Bardy GH
Circulation; 2009 Dec; 120(22):2170-6. PubMed ID: 19917887
[TBL] [Abstract][Full Text] [Related]
8. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
[TBL] [Abstract][Full Text] [Related]
9. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.
Owens DK; Sanders GD; Heidenreich PA; McDonald KM; Hlatky MA
Am Heart J; 2002 Sep; 144(3):440-8. PubMed ID: 12228780
[TBL] [Abstract][Full Text] [Related]
10. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
[TBL] [Abstract][Full Text] [Related]
11. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
Russo AM; Poole JE; Mark DB; Anderson J; Hellkamp AS; Lee KL; Johnson GW; Domanski M; Bardy GH
J Cardiovasc Electrophysiol; 2008 Jul; 19(7):720-4. PubMed ID: 18373605
[TBL] [Abstract][Full Text] [Related]
12. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
[TBL] [Abstract][Full Text] [Related]
14. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
[TBL] [Abstract][Full Text] [Related]
15. Are implantable cardioverter-defribrillators always superior to amiodarone?
Doggrell SA
Expert Opin Pharmacother; 2003 Nov; 4(11):2111-4. PubMed ID: 14596664
[TBL] [Abstract][Full Text] [Related]
16. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population.
Levy WC; Lee KL; Hellkamp AS; Poole JE; Mozaffarian D; Linker DT; Maggioni AP; Anand I; Poole-Wilson PA; Fishbein DP; Johnson G; Anderson J; Mark DB; Bardy GH
Circulation; 2009 Sep; 120(10):835-42. PubMed ID: 19704100
[TBL] [Abstract][Full Text] [Related]
17. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.
Poole JE; Olshansky B; Mark DB; Anderson J; Johnson G; Hellkamp AS; Davidson-Ray L; Fishbein DP; Boineau RE; Anstrom KJ; Reinhall PG; Packer DL; Lee KL; Bardy GH;
J Am Coll Cardiol; 2020 Jul; 76(4):405-415. PubMed ID: 32703511
[TBL] [Abstract][Full Text] [Related]
19. Key clinical insights from the sudden cardiac death in heart failure trial.
Anderson J; Bardy GH
J Cardiovasc Nurs; 2006; 21(6):463-8. PubMed ID: 17293736
[TBL] [Abstract][Full Text] [Related]
20. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study.
Cappato R
Am J Cardiol; 1999 Mar; 83(5B):68D-73D. PubMed ID: 10089843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
